BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

819 related articles for article (PubMed ID: 16127219)

  • 1. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves' thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves' disease.
    Izumi Y; Takeoka K; Amino N
    Endocr J; 2005 Aug; 52(4):493-7. PubMed ID: 16127219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease.
    Zimmermann-Belsing T; Nygaard B; Rasmussen AK; Feldt-Rasmussen U
    Eur J Endocrinol; 2002 Feb; 146(2):173-7. PubMed ID: 11834425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TSH receptor antibody measurements and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs.
    Okamoto Y; Tanigawa S; Ishikawa K; Hamada N
    Endocr J; 2006 Aug; 53(4):467-72. PubMed ID: 16820704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial changes in liver function tests in patients with thyrotoxicosis induced by Graves' disease and painless thyroiditis.
    Kubota S; Amino N; Matsumoto Y; Ikeda N; Morita S; Kudo T; Ohye H; Nishihara E; Ito M; Fukata S; Miyauchi A
    Thyroid; 2008 Mar; 18(3):283-7. PubMed ID: 18001177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simple and practical parameters for differentiation between destruction-induced thyrotoxicosis and Graves' thyrotoxicosis.
    Izumi Y; Hidaka Y; Tada H; Takano T; Kashiwai T; Tatsumi KI; Ichihara K; Amino N
    Clin Endocrinol (Oxf); 2002 Jul; 57(1):51-8. PubMed ID: 12100069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Painless thyroiditis mimicking relapse of hyperthyroidism during or after potassium iodide or thionamide therapy for Graves' disease resulting in remission.
    Okamura K; Sato K; Fujikawa M; Bandai S; Ikenoue H; Kitazono T
    Endocr J; 2023 Feb; 70(2):207-222. PubMed ID: 36351595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the 2nd generation radio-receptional assay for anti-TSH receptor antibodies (TRAb) in autoimmune thyroid diseases. Comparison with 1st generation and anti-thyroperoxidase antibodies (AbTPO).
    Giovanella L; Ceriani L; Garancini S
    Q J Nucl Med; 2001 Mar; 45(1):115-9. PubMed ID: 11456370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation of postpartum Graves' thyrotoxicosis from postpartum destructive thyrotoxicosis using antithyrotropin receptor antibodies and thyroid blood flow.
    Ide A; Amino N; Kang S; Yoshioka W; Kudo T; Nishihara E; Ito M; Nakamura H; Miyauchi A
    Thyroid; 2014 Jun; 24(6):1027-31. PubMed ID: 24400892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease.
    Ota H; Amino N; Morita S; Kobayashi K; Kubota S; Fukata S; Kamiyama N; Miyauchi A
    Clin Endocrinol (Oxf); 2007 Jul; 67(1):41-5. PubMed ID: 17437515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
    Glinoer D; de Nayer P; Bex M;
    Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical applications of the 2nd generation assay for anti-TSH receptor antibodies in Graves' disease. Evaluation in patients with negative 1st generation test.
    Giovanella L; Ceriani L; Garancini S
    Clin Chem Lab Med; 2001 Jan; 39(1):25-8. PubMed ID: 11256796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The incidence of gestational hyperthyroidism and postpartum thyroiditis in treated patients with Graves' disease.
    Tagami T; Hagiwara H; Kimura T; Usui T; Shimatsu A; Naruse M
    Thyroid; 2007 Aug; 17(8):767-72. PubMed ID: 17651013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict Graves' Disease Relapse.
    Tun NN; Beckett G; Zammitt NN; Strachan MW; Seckl JR; Gibb FW
    Thyroid; 2016 Aug; 26(8):1004-9. PubMed ID: 27266892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.
    Cappelli C; Gandossi E; Castellano M; Pizzocaro C; Agosti B; Delbarba A; Pirola I; De Martino E; Rosei EA
    Endocr J; 2007 Dec; 54(5):713-20. PubMed ID: 17675761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves' disease treated using antithyroid medication.
    Smith J; Brown RS
    Thyroid; 2007 Nov; 17(11):1103-7. PubMed ID: 17822376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.